MOLN earnings

Specific tumor accumulation and attractive biodistribution highly supportive of MP0712 clinical development for treatment of DLL3-expressing cancersDosimetry data highlight Radio-DARPins as vector for precise delivery of potent alpha-emitting isotopes to tumorsMP0712 Phase 1/2a study open in U.S. with initial clinical data expected in 2026Molecular Partners to host conference call February 2 at 8AM ET (2PM CET), joined by renowned nuclear medicine expert Prof. Ken Herrmann, M.D. ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company deve

Case study with first patient images of half-life engineered MP0712 from compassionate care use show specific uptake in primary tumors and metastatic lesions MP0712 Radio-DARPin leverages rapid internalization & replenishment of DLL3 to achieve high accumulation in tumor cells Phase 1 IND for MP0712 filed, clinical trial initiation expected before end-2025 in US with initial data expected in 2026 Molecular Partners to host conference call today, November 12 at 10AM ET (4PM CET) ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company de

MP0533 data presented at European Hematology Association (EHA) highlights improved response rates and antitumor activity in low disease burden patients; additional data under amended dosing scheme expected in Q4 2025IND filing on first radio-DARPin program MP0712 and initiation of Phase 1 trial expected by end 2025; update on early imaging work planned in Q4 2025; expanded strategic radiotherapy partnership with Orano MedAppointed Martin Steegmaier, Ph.D. as CSO and member of Executive CommitteeCash and cash equivalents and short-term time deposits total of CHF 114 million as of June 30, 2025, extending runway into 2028. ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Aug. 25, 2025 (GL

Clinical programs on track, with two major milestones later this year, and cash position, CHF 131 million as of March 31, 2025, expected to provide funding well into 2027IND filing and initial clinical data on first targeted Radio-DARPin therapy program, MP0712, expected in 2025; strategic partnership with Orano Med expanded from four to ten programsData from dosing cohort 8 in Phase 1/2a trial of MP0533 demonstrate increased rates and depth of responses; study protocol amendment now approved, and dosing cohort 9 enrollment initiated, additional data expected in 2025 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 15, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53

Participation in fireside chats at TD Cowen and Leerink healthcare conferencesCall on 2024 financial results on March 7 at 2.00 pm CET (8.00 am ET) ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics ("Molecular Partners" or the "Company"), today announced its attendance and presentations at upcoming investor conferences. Molecular Partners will also host a conference call on March 7 on its full-year 2024 financial report. The Annual Report is due to be published March 6. Details of the events:

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 01, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that it will issue its fourth quarter and full year financial results for 2023 on March 14, which will be followed by a conference call the next day to discuss the results. Molecular Partners' Chief Executive Officer Patrick Amstutz will also present at the 44th Annual Cowen Health Care Conference taking place in Boston, MA, and will participate in the Leerink Global Biopharma Conference taking place in Miami, FL along with oth

Phase 1/2a clinical trial of tetraspecific T cell engager candidate MP0533 initiated in patients with relapsed/refractory AML and MDS/AML; dosing ongoing in the 4th dose cohort; initial data expected in Q4 2023 Positive MP0317 data of ongoing Phase 1 clinical trial presented at ASCO confirm proposed MOA and indicates favorable safety profile in patients with advanced solid tumors, supporting future combination studies with potential partners; presently finalizing recruitment of weekly dosing regimen Preclinical data supporting the Radio DARPin Therapy platform presented at leading conferences TAT12, AACR and SNMMI in H1 2023 Funded well into 2026 with cash of CHF 218 million as of June 30

Research & Development Highlights: Initiated Phase 1 study of MP0533, a novel tri-specific T-cell engager for the treatment of acute myeloid leukemia (AML) and high risk myelodysplastic syndrome (MDS)Presented preclinical data supporting the unique design and mechanism of MP0533 at the 64th American Society of Hematology (ASH) Annual Meeting and ExpositionEstablished Radio DARPin Therapy (RDT) Platform, formally selecting tumor-associated protein Delta-like ligand 3 (DLL3) as a first targetPresented interim safety and mechanism data from ongoing Phase 1 study of MP0317 for the treatment of solid tumors at the 37th Society for Immunotherapy of Cancer (SITC) Annual MeetingSigned in early Janu

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, will issue a press release summarizing its highlights and financial results for the fourth quarter and full year of 2022, followed by an investor call the following day. Chief Executive Officer Patrick Amstutz will also deliver a company presentation at the 43rd Annual Cowen Health Care Conference in Boston, MA. Please see all details below: Conference Presentation Details: Cowen Health Care ConferenceMarch 8, 2023, at 9:10am ET (3:10pm CET)B

Continued development of MP0317, with initial clinical data from Phase 1 study expected in the second half of 2022Initiation of Phase 1 study for MP0533 expected by year endContinued progression of proprietary DARPin-conjugated radioligand therapeutics; innate immune cell engagers; next-generation T-cell engagers; and antiviral DARPinsMP0310 Phase 1 enrollment complete; no additional studies currently plannedIn January 2022, Molecular Partners received a payment of CHF 150 million from Novartis to license ensovibepNovartis is responsible for further development, manufacturing, and commercialization activities. An application for Emergency Use Authorization (EUA) was submitted to the U.S. Foo

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, will issue a press release summarizing its highlights and financial results for the first half-year of 2022, followed by an analyst & investor call the following day. Please see more details here: Release date and time August 25, 2022, 4:30 pm ET (10:30 pm CET) Call Details: August 26, 2022, 8:00 am ET (2:00 pm CET) The half year 2022 results presentation will be webcast live and will be made available on the Company's website under the inv

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb. 25, 2022 (GLOBE NEWSWIRE) -- Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that its Chief Executive Officer, Patrick Amstutz, Ph.D., will participate in two upcoming healthcare investor events in March, 2022. In addition, the Company will publish its full year 2021 annual report on March 15 and hold an investor conference call on March 16, 2021. Presentation Details: Cowen Health Care Conference – Fireside chat Wednesday, March 9, 2022 at 2:10-2:40pm ET Conference Participation Detai